Alnylam's collaborator, Regeneron, announced positive first-in-human clinical trial results for CIDEBsiRNA, an RNAi therapeutic for MASLD. The drug rapidly normalized liver fat and improved liver injury markers, indicating significant potential for this treatment and validating Alnylam's RNAi platform.
Alnylam's collaborator, Regeneron, reported promising first-in-human results for CIDEBsiRNA, an RNAi therapeutic targeting MASLD. The study showed a single dose rapidly normalized liver fat and improved liver injury markers, which is a significant positive for both companies. This validates Alnylam's RNAi technology platform and strengthens its pipeline, while for Regeneron, it represents a potential new blockbuster drug in a large market. Short-term, this could lead to increased investor confidence and a boost in stock prices for both ALNY and REGN. Long-term, successful development of CIDEBsiRNA could unlock substantial revenue streams and further solidify Alnylam's position as a leader in RNAi therapeutics, and Regeneron's in metabolic diseases. The key opportunity for traders is the potential for continued positive news as the drug progresses through further clinical trials.